Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quyushengxin (QYSX) is a traditional Chinese medicine (TCM) formula being investigated for the treatment of mild-to-moderate ulcerative colitis (UC). [1, 2] The formula is primarily composed of four herbs: Panax ginseng, Astragalus membranaceus, Pulsatilla chinensis, and Coptis chinensis. [2] Clinical studies have shown that Quyushengxin, both alone and in combination with mesalazine, can relieve clinical symptoms, suppress inflammation, and improve the quality of life for UC patients. [1] Its mechanism of action is believed to be multifactorial, involving the regulation of the gut microbiome and bacteriophages, restoring the balance of gut flora. [3] Research also suggests it works by modulating bile acid metabolism and promoting the polarization of macrophages from a pro-inflammatory M1 state to an anti-inflammatory M2 state, which helps reduce inflammation and promote tissue repair. [10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quyushengxin.